384 related articles for article (PubMed ID: 25697478)
1. Anticipating designer drug-resistant cancer cells.
Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
[TBL] [Abstract][Full Text] [Related]
2. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
Horlings HM; Shah SP; Huntsman DG
JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
[No Abstract] [Full Text] [Related]
3. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
4. Lack of access to targeted cancer therapy.
Burki TK
Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
[No Abstract] [Full Text] [Related]
5. Drug sensitivity testing platforms for gastric cancer diagnostics.
Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
[TBL] [Abstract][Full Text] [Related]
6. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
[TBL] [Abstract][Full Text] [Related]
7. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
8. Personalising the treatment of prostate cancer.
Gunjur A
Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
[No Abstract] [Full Text] [Related]
9. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
10. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
Wijdeven RH; Pang B; Assaraf YG; Neefjes J
Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
[TBL] [Abstract][Full Text] [Related]
11. JAMA Oncology Patient Page. The Evolution of a Cancer.
West HJ; Jin JO
JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697
[No Abstract] [Full Text] [Related]
12. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
13. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
Schram AM; Chang MT; Jonsson P; Drilon A
Nat Rev Clin Oncol; 2017 Dec; 14(12):735-748. PubMed ID: 28857077
[TBL] [Abstract][Full Text] [Related]
14. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.
NicoĊ M; Wojas-Krawczyk K; Krawczyk P; Milanowski J
Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118
[TBL] [Abstract][Full Text] [Related]
15. Mapping the Pathways of Resistance to Targeted Therapies.
Wood KC
Cancer Res; 2015 Oct; 75(20):4247-51. PubMed ID: 26392071
[TBL] [Abstract][Full Text] [Related]
16. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
17. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
19. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
20. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
